ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the the trial is to establish one of three study arms, as future
standard based on the comparison of the investigator-assessed failure-free survival.